An angiopoietin 2, FGF23, and BMP10 biomarker signature differentiates atrial fibrillation from other concomitant cardiovascular conditions.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 10 2023
05 10 2023
Historique:
received:
24
10
2022
accepted:
08
09
2023
medline:
1
11
2023
pubmed:
6
10
2023
entrez:
5
10
2023
Statut:
epublish
Résumé
Early detection of atrial fibrillation (AF) enables initiation of anticoagulation and early rhythm control therapy to reduce stroke, cardiovascular death, and heart failure. In a cross-sectional, observational study, we aimed to identify a combination of circulating biomolecules reflecting different biological processes to detect prevalent AF in patients with cardiovascular conditions presenting to hospital. Twelve biomarkers identified by reviewing literature and patents were quantified on a high-precision, high-throughput platform in 1485 consecutive patients with cardiovascular conditions (median age 69 years [Q1, Q3 60, 78]; 60% male). Patients had either known AF (45%) or AF ruled out by 7-day ECG-monitoring. Logistic regression with backward elimination and a neural network approach considering 7 key clinical characteristics and 12 biomarker concentrations were applied to a randomly sampled discovery cohort (n = 933) and validated in the remaining patients (n = 552). In addition to age, sex, and body mass index (BMI), BMP10, ANGPT2, and FGF23 identified patients with prevalent AF (AUC 0.743 [95% CI 0.712, 0.775]). These circulating biomolecules represent distinct pathways associated with atrial cardiomyopathy and AF. Neural networks identified the same variables as the regression-based approach. The validation using regression yielded an AUC of 0.719 (95% CI 0.677, 0.762), corroborated using deep neural networks (AUC 0.784 [95% CI 0.745, 0.822]). Age, sex, BMI and three circulating biomolecules (BMP10, ANGPT2, FGF23) are associated with prevalent AF in unselected patients presenting to hospital. Findings should be externally validated. Results suggest that age and different disease processes approximated by these three biomolecules contribute to AF in patients. Our findings have the potential to improve screening programs for AF after external validation.
Identifiants
pubmed: 37798357
doi: 10.1038/s41598-023-42331-7
pii: 10.1038/s41598-023-42331-7
pmc: PMC10556075
doi:
Substances chimiques
Angiopoietin-2
0
Biomarkers
0
BMP10 protein, human
0
Bone Morphogenetic Proteins
0
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16743Subventions
Organisme : British Heart Foundation
ID : FS/13/43/30324
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/16/12/32451
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/12/3/29609
Pays : United Kingdom
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : British Heart Foundation
ID : AA/18/2/34218
Pays : United Kingdom
Informations de copyright
© 2023. Springer Nature Limited.
Références
Hindricks, G. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 1, 1 (2020).
January, C. T. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society. J. Am. Coll. Cardiol. 74(1), 104–132 (2019).
doi: 10.1016/j.jacc.2019.01.011
pubmed: 30703431
Grond, M. et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: A prospective multicenter cohort study. Stroke 44(12), 3357–3364 (2013).
doi: 10.1161/STROKEAHA.113.001884
pubmed: 24130137
Kirchhof, P. et al. Early rhythm-control therapy in patients with atrial fibrillation. N. Engl. J. Med. 1, 1 (2020).
Freedman, B. et al. Screening for atrial fibrillation: A report of the AF-SCREEN international collaboration. Circulation 135(19), 1851–1867 (2017).
doi: 10.1161/CIRCULATIONAHA.116.026693
pubmed: 28483832
Svennberg, E. et al. Mass screening for untreated atrial fibrillation: The STROKESTOP study. Circulation 131(25), 2176–2184 (2015).
doi: 10.1161/CIRCULATIONAHA.114.014343
pubmed: 25910800
Fabritz, L. et al. Smartphone and wearable detected atrial arrhythmias in older adults: Results of a fully digital European Case finding study. Eur. Heart J. Digit. Health 3(4), 610–625 (2022).
doi: 10.1093/ehjdh/ztac067
pubmed: 36710894
pmcid: 9779806
Rizas, K. D. et al. Smartphone-based screening for atrial fibrillation: A pragmatic randomized clinical trial. Nat. Med. 28(9), 1823–1830 (2022).
doi: 10.1038/s41591-022-01979-w
pubmed: 36031651
Kemp Gudmundsdottir, K. et al. Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide: the STROKESTOP II study. Europace 22(1), 24–32 (2020).
doi: 10.1093/europace/euz255
pubmed: 31790147
Staerk, L. et al. Protein biomarkers and risk of atrial fibrillation: The FHS. Circ. Arrhythm. Electrophysiol. 13(2), e007607 (2020).
doi: 10.1161/CIRCEP.119.007607
pubmed: 31941368
pmcid: 7031024
Marott, S. C. et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J. Am. Coll. Cardiol. 56(10), 789–795 (2010).
doi: 10.1016/j.jacc.2010.02.066
pubmed: 20797493
Chua, W. et al. Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation. Eur. Heart J. 40(16), 1268–1276 (2019).
doi: 10.1093/eurheartj/ehy815
pubmed: 30615112
pmcid: 6475521
Mehta, R. et al. Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardiol. 1(5), 548–556 (2016).
doi: 10.1001/jamacardio.2016.1445
pubmed: 27434583
pmcid: 4992989
Chua, W. et al. Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study. PLoS Med. 18(2), e1003405 (2021).
doi: 10.1371/journal.pmed.1003405
pubmed: 33534825
pmcid: 7857735
Fabritz, L. et al. Expert consensus document: Defining the major health modifiers causing atrial fibrillation: A roadmap to underpin personalized prevention and treatment. Nat. Rev. Cardiol. 13(4), 230–237 (2016).
doi: 10.1038/nrcardio.2015.194
pubmed: 26701216
Kotecha, D. et al. Integrating new approaches to atrial fibrillation management: The 6th AFNET/EHRA Consensus Conference. Europace 20(3), 395–407 (2018).
doi: 10.1093/europace/eux318
pubmed: 29300976
Kirchhof, P. et al. Early and comprehensive management of atrial fibrillation: Executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference “research perspectives in AF”. Eur. Heart J. 30(24), 2969–2977 (2009).
doi: 10.1093/eurheartj/ehp235
pubmed: 19535417
Chua, W. et al. Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: A protocol for the analysis of the CATCH ME combined dataset. BMC Cardiovasc. Disord. 19(1), 120 (2019).
doi: 10.1186/s12872-019-1105-4
pubmed: 31113362
pmcid: 6528378
Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604–612 (2009).
doi: 10.7326/0003-4819-150-9-200905050-00006
pubmed: 19414839
pmcid: 2763564
Sauerbrei, W. The use of resampling methods to simplify regression models in medical statistics. J. R. Stat. Soc. Ser. C Appl. Stat. 48, 313–329 (1999).
doi: 10.1111/1467-9876.00155
R Core Team, R: A language and environment for statistical computing. 2017, R Foundation for Statistical Computing: Vienna, Austria.
Alonso, A. et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: The CHARGE-AF consortium. J. Am. Heart Assoc. 2(2), e000102 (2013).
doi: 10.1161/JAHA.112.000102
pubmed: 23537808
pmcid: 3647274
Richards, M. et al. Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: Results from the BACH Study (Biomarkers in ACute Heart Failure). JACC Heart Fail. 1(3), 192–199 (2013).
doi: 10.1016/j.jchf.2013.02.004
pubmed: 24621869
Brady, P. F. et al. Interactions between atrial fibrillation and natriuretic peptide in predicting heart failure hospitalization or cardiovascular death. J. Am. Heart Assoc. 11(4), e022833 (2022).
doi: 10.1161/JAHA.121.022833
pubmed: 35112889
pmcid: 9245805
Hijazi, Z. et al. Bone morphogenetic protein 10: a novel risk marker of ischaemic stroke in patients with atrial fibrillation. Eur. Heart J. 44(3), 208–218 (2023).
doi: 10.1093/eurheartj/ehac632
pubmed: 36380569
Hennings, E. et al. Bone morphogenetic protein 10-A novel biomarker to predict adverse outcomes in patients with atrial fibrillation. J. Am. Heart Assoc. 12(6), e028255 (2023).
doi: 10.1161/JAHA.122.028255
pubmed: 36926939
pmcid: 10111531
Goette, A. et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. Heart Rhythm 14(1), e3–e40 (2017).
doi: 10.1016/j.hrthm.2016.05.028
pubmed: 27320515
Fabritz, L. et al. Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: The 7th AFNET/EHRA Consensus Conference. Europace 23(3), 329–344 (2021).
doi: 10.1093/europace/euaa279
pubmed: 33555020
Morrell, N. W. et al. Targeting BMP signalling in cardiovascular disease and anaemia. Nat. Rev. Cardiol. 13(2), 106–120 (2016).
doi: 10.1038/nrcardio.2015.156
pubmed: 26461965
Reyat, J. S. et al. Reduced left atrial cardiomyocyte PITX2 and elevated circulating BMP10 predict atrial fibrillation after ablation. JCI Insight 5(16), 1 (2020).
doi: 10.1172/jci.insight.139179
Litvinukova, M. et al. Cells of the adult human heart. Nature 1, 1 (2020).
Piek, A. et al. A combined bioinformatics, experimental and clinical approach to identify novel cardiac-specific heart failure biomarkers: Is Dickkopf-3 (DKK3) a possible candidate?. Eur. J. Heart Fail. 1, 1 (2020).
Meyre, P. B. et al. Biomarkers associated with rhythm status after cardioversion in patients with atrial fibrillation. Sci. Rep. 12(1), 1680 (2022).
doi: 10.1038/s41598-022-05769-9
pubmed: 35102265
pmcid: 8803959
Staszewsky, L. et al. Total NT-proBNP, a novel biomarker related to recurrent atrial fibrillation. BMC Cardiovasc. Disord. 21(1), 553 (2021).
doi: 10.1186/s12872-021-02358-y
pubmed: 34798808
pmcid: 8603582
Akwii, R. G. et al. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells 8(5), 1 (2019).
doi: 10.3390/cells8050471
Fiedler, U. et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103(11), 4150–4156 (2004).
doi: 10.1182/blood-2003-10-3685
pubmed: 14976056
Freestone, B. et al. Angiogenic factors in atrial fibrillation: A possible role in thrombogenesis?. Ann. Med. 37(5), 365–372 (2005).
doi: 10.1080/07853890510037392
pubmed: 16179272
Law, J. P. et al. Clinical potential of targeting fibroblast growth Factor-23 and alphaKlotho in the treatment of uremic cardiomyopathy. J. Am. Heart. Assoc. 9(7), e016041 (2020).
doi: 10.1161/JAHA.120.016041
pubmed: 32212912
pmcid: 7428638
Schnabel, R. B. et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: The 8th AFNET/EHRA consensus conference. Europace 25(1), 6–27 (2023).
doi: 10.1093/europace/euac062
pubmed: 35894842
Kirchhof, P. et al. Anticoagulation with Edoxaban in patients with atrial high-rate episodes. N. Engl. J. Med. 1, 1 (2023).
Lopes, R. D. et al. Rationale and design of the apixaban for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation (ARTESiA) trial. Am. Heart J. 189, 137–145 (2017).
doi: 10.1016/j.ahj.2017.04.008
pubmed: 28625370